Glyzenta Duo Tablet 2.5/850 mg
Linagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Aju Pharmaceutical Co., Ltd.
MFDS item code 201902225 · Approved 2019.04.11
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication helps patients with type 2 diabetes achieve more effective blood glucose control when combined with dietary and exercise therapy. The combination of linagliptin and metformin works together to help maintain stable blood glucose levels. It is especially suitable for those who find it difficult to control their blood glucose levels with existing dietary and exercise therapies alone. Consistent intake will result in improved blood glucose control, significantly aiding diabetes management.
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each ingredient: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy whose blood glucose cannot be adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily, which may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients whose blood glucose cannot be adequately controlled with metformin monotherapy: The initial dose of this medicine should be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose cannot be adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Cautious Administration). 5. Patients whose blood glucose cannot be adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Cautious Administration). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may result in changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medicine).
This medication is used for the treatment of type 2 diabetes and aids in blood glucose control. Do not use this medication in patients with decreased kidney function or liver dysfunction. Particularly, in cases of severe renal impairment, taking this medication can result in a serious side effect known as lactic acidosis, posing significant risk. Lactic acidosis is a rare but very dangerous condition, with symptoms including abdominal pain, muscle pain, weakness, respiratory distress, and hypothermia. If such symptoms occur, seek medical attention immediately. It is advisable not to administer this medication to pregnant or breastfeeding women, and consultation with a doctor is necessary if planning to become pregnant. Additionally, during the course of taking this medication, regular checks on kidney function and vitamin B12 levels should be conducted to identify any abnormalities. There may be an increased risk of hypoglycemia when taken with sulfonylureas or insulin, so blood glucose levels should be monitored closely. This medication should be temporarily suspended in situations that may cause a temporary decline in kidney function, such as acute infections, dehydration, severe trauma, pre- and post-operative states, and administration of radiocontrast agents. This medication may cause side effects including gastrointestinal disorders, diarrhea, abdominal pain, and vomiting, and may rarely result in symptoms like pancreatitis, skin rash, or joint pain. If severe abdominal pain, indicative of acute pancreatitis, occurs, discontinue the medication immediately and consult healthcare personnel. This medication is not recommended for children and dosage adjustments should be made for elderly patients considering their kidney function. While taking this medication, it is advisable to avoid alcohol. There may be interactions with other medications, so it is essential to inform a doctor or pharmacist of all current medications. Finally, this medication should be stored out of reach of children and kept away from moisture.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, to maintain the efficacy of the medication, it is best stored at room temperature between 1°C and 30°C.
Bright orange, biconvex, oval-shaped film-coated tablet
10 tablets/bottle, 30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle, 30 tablets/box (10 tablets/PTP×3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Aju Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.